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Abstract 
Background: Hepatic cirrhosis is a seriously chronic degenerative 
disease in which normal liver cells are damaged and are replaced by scar 
tissue. Ascites is the most frequent complication that happened in hepatic 
cirrhosis and need to be managed properly, especially in the cost 
effectiveness analysis. Cost Effectiveness Analysis is a form of 
Pharmacoeconomic study that evaluates and compares the cost and the 
clinical outcome of two or more treatments. 
Objective: The purpose of this research is to compare the cost-
effectiveness of 3 kinds of Ascites treatments: bolus intravenous Furosemid 
versus combination of oral Spironolakton and bolus intravenous Furosemid 
versus combination of oral Spironolakton, oral Furosemid and bolus 
intravenous Furosemid. 
Method: Subjects (N = 29) were hepatic cirrhosis patients with 
ascites, and their age ranging from 34 to 85 years old. Data were collected 
from Adi Husada Undaan Wetan Hospital, Surabaya, from January 2010 to 
December 2011, using the retrospective approach. The sampling method 
used is purposive sampling. The measurement of cost was based on the 
cost of the drug used for the treatment and the effectiveness of the treatment 
is calculated based on the measurement of the increase of urine collection 
and the length of therapy. Data were analysed with Kruskal Wallis method 
and by calculating the value of Average Cost Effectiveness Ratio (ACER).  
Result: The value of ACER for Furosemid bolus intravenous was IDR 
139,800, for oral Spironolakton and Furosemid bolus intravenous was IDR 
158,763 and for Spironolakton oral and Furosemid oral and Furosemid bolus 
intravenous was IDR 332,337. 
Conclusion: This study showed that Ascites treatment with 
Furosemid bolus intravenous is most cost-effective. This result supports the 
preparation of the formulary with an alternative therapy which is more cost-
effective. 
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